ArticleGastrointestinal endoscopy2022
Outcomes for endoscopic submucosal dissection of pathologically staged T1b esophageal cancer: a multicenter study.
Article in Gastrointestinal endoscopy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett's Esophagus and Related Neoplasia.Gastroenterology · 2024Guideline
- Clinicopathological features in T1 adenocarcinoma of the esophagogastric junction: a new perspective on tumor localization.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Risk factors for non-curative resection after endoscopic submucosal dissection for early esophageal lesions and analysis of secondary treatment efficacy.Surgical endoscopy · 2026Article
- Expanded Indications in Advanced Endoscopic Resection of Malignant Gastrointestinal Lesions.Current gastroenterology reports · 2026Review
- Comparison of long-term outcomes between endoscopic submucosal dissection and esophagectomy for superficial esophageal squamous cell carcinoma.Gastroenterology report · 2026Article
- Clinical features of early esophageal neoplastic lesions at different stages and efficacy and prognosis after endoscopic submucosal dissection.World journal of gastroenterology · 2025Article
- Risk factors associated with poor prognosis after endoscopic treatment of clinical T1a esophageal cancer.Surgical endoscopy · 2025Article
- Navigating Endoscopic Surveillance and Management of Barrett's Esophagus in Elderly Patients: Balancing the Risks and Benefits.Current gastroenterology reports · 2025Review
- Review
- From endoscopy to surgery: a translational perspective on early esophageal cancer management.Frontiers in medicine · 2025Article
- Journey to complete remission of dysplasia and intestinal metaplasia after ESD and EMR of Barrett's esophagus-related neoplasia.Endoscopy international open · 2025Article
- Challenges in early detection and endoscopic resection of esophageal cancer: There is a long way to go.World journal of gastrointestinal oncology · 2024Article
- Endoscopic submucosal dissection (ESD) outcomes in T1B esophageal cancer: a retrospective study.Surgical endoscopy · 2024Article
- Esophageal cancer screening, early detection and treatment: Current insights and future directions.World journal of gastrointestinal oncology · 2024Review
- Esophagectomy versus observation following endoscopic submucosal dissection of pT1b esophageal adenocarcinoma.Surgical endoscopy · 2024Article
- Endoscopic diagnosis and management of superficial esophageal squamous cell carcinoma.Revista da Associacao Medica Brasileira (1992) · 2024Article
- Article
- Endoscopic submucosal dissectionTherapeutic advances in gastroenterology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
21 authors at 8 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
aimsThe outcomes of endoscopic submucosal dissection (ESD) for T1b esophageal cancer (EC) and its recurrence rates remain unclear in the West. Using a multicenter cohort, we evaluated technical outcomes and recurrence rates of ESD in the treatment of pathologically staged T1b EC.
methodsWe included patients who underwent ESD of T1b EC at 7 academic tertiary referral centers in the United States (n = 6) and Brazil (n = 1). We analyzed demographic, procedural, and histopathologic characteristics and follow-up data. Time-to-event analysis was performed to evaluate recurrence rates.
resultsSixty-six patients with pathologically staged T1b EC after ESD were included in the study. A preprocedure staging EUS was available in 54 patients and was Tis/T1a in 27 patients (50%) and T1b in 27 patients (50%). En-bloc resection rate was 92.4% (61/66) and R0 resection rate was 54.5% (36/66). Forty-nine of 66 patients (74.2%) did not undergo surgery immediately after resection and went on to surveillance. Ten patients had ESD resection within the curative criteria, and no recurrences were seen in a 13-month (range, 3-18.5) follow-up period in these patients. Ten of 39 patients (25.6%) with noncurative resections had residual/recurrent disease. Of the 10 patients with noncurative resection, local recurrence alone was seen in 5 patients (12.8%) and metastatic recurrence in 5 patients (12.8%). On univariate analysis, R1 resection had a higher risk of recurrent disease (hazard ratio, 6.25; 95% confidence interval, 1.29-30.36; P = .023).
conclusionsEUS staging of T1b EC has poor accuracy, and a staging ESD should be considered in these patients. ESD R0 resection rates were low in T1b EC, and R1 resection was associated with recurrent disease. Patients with noncurative ESD resection of T1b EC who cannot undergo surgery should be surveyed closely, because recurrent disease was seen in 25% of these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.